These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9783400)

  • 1. [An evaluation of the epidemiological and economic efficacy of immunizing adults with the Vaxigrippe vaccine].
    Sharipova IS; Kuz'minykh SI; Fel'dblium IV
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):46-9. PubMed ID: 9783400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effectiveness of using the Vaxigrip vaccine from the firm of Pasteur Mérieux Connaught for influenza prevention in organized groups of adults].
    Sharipova IS; Fel'dblium IV; Kuz'minykh SI; Nikolova IV; Padrul' MM; Sharipov MS; Nikul'shin AA; Kol'tsova AA
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (3):37-41. PubMed ID: 10851988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific prophylaxis of influenza in organized groups of children with the vaccine Vaxigrip].
    Zaplatnikov AL
    Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):36-40. PubMed ID: 11881493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The prophylactic efficacy of the trivalent polymer-subunit influenza vaccine Grippol (3)].
    El'shina GA; Gorbunov MA; Shervarli VI; Lonskaia NI; Khaitov RM; Nekrasov AV; Ivanova AS; Matrosovich MN; Puchkova NG; Pavlova LI; Malinovskiĭ AA
    Voen Med Zh; 1997 Feb; 318(2):47-9. PubMed ID: 9148581
    [No Abstract]   [Full Text] [Related]  

  • 5. [Specific prophylaxis of influenza with inactivated split vaccine Vaxigrip].
    Semenenko TA; Sel'kova EP; Gendon IuZ
    Zh Mikrobiol Epidemiol Immunobiol; 2004; (4):109-14. PubMed ID: 15481939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiological and economic effectiveness of immunization of adult and children against influenza and acute respiratory viral infections with the vaccine Grippol].
    Khaitov RM; Nekrasov AV; Puchkova NG; Ivanova AS
    Zh Mikrobiol Epidemiol Immunobiol; 2003; (3):83-6. PubMed ID: 12886641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of influenza vaccine Vaxigrip in the combined immunization of conscripts during influenza seasons of 2002-2003].
    Burtseva EI; Vlasova LN; Shevchenko ES; Sabanin IuV; Rikhter VV; Artiukov RM; Rybin VV; Tarasevich NN; Slepushkin AN
    Zh Mikrobiol Epidemiol Immunobiol; 2004; (1):49-55. PubMed ID: 15024982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The evaluation of the epidemiological efficacy of 3-component inactivated influenza vaccines using an intranasal application method].
    Marinich IG; Iaroshevskaia IIu; Konareva AL; Lonskaia NI; Shadrin AS; Salmin LV
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):76-8. PubMed ID: 8079581
    [No Abstract]   [Full Text] [Related]  

  • 9. [Efficiency of "Vaxigrip" vaccine in the complex immunization of servicemen].
    Burtseva EI; Rikhter VV; Sabanin IuV; Slepushkin AN; Vlasova LN; Shevchenko ES; Artiukov PM; Rybin VV; Tarasevich NN
    Voen Med Zh; 2003 Oct; 324(10):41-5. PubMed ID: 14671894
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
    Arnoux S; Weinberger C; Gessner BD
    Vaccine; 2007 Nov; 25(45):7720-31. PubMed ID: 17920168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of the prophylactic effectiveness of an inactivated influenza vaccine by immunizing schoolchildren in the springtime].
    Vasil'eva RI; Liamtseva GA; Riazantseva TG; Oleĭnikova EV; Sosunov AV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):10-4. PubMed ID: 2939666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M; Bricout H; Clay E; Largeron N
    Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuing influenza vaccine: medical, economic, and social benefits.
    Poland GA
    Clin Infect Dis; 2009 Feb; 48(3):299-301. PubMed ID: 19115975
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
    Haugh M; Gresset-Bourgeois V; Macabeo B; Woods A; Samson SI
    Expert Rev Vaccines; 2017 Jun; 16(6):545-564. PubMed ID: 28460594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. French economic evaluations of influenza and influenza vaccination.
    Levy E
    Pharmacoeconomics; 1996; 9 Suppl 3():62-6. PubMed ID: 10160489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.
    Chabanon AL; Bricout H; Ballandras C; Souverain A; Caroe TD; Butler KM
    Hum Vaccin Immunother; 2018 Feb; 14(2):378-385. PubMed ID: 29148911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Body immunocorrection when vaccination is contraindicated (a clinico-epidemiological validation)].
    Furgal SM; Degtiarev AA; Zemskov AM
    Voen Med Zh; 1992 Aug; (8):31-4. PubMed ID: 1441268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age.
    Allsup S; Gosney M; Haycox A; Regan M
    Health Technol Assess; 2003; 7(24):iii-x, 1-65. PubMed ID: 14499051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of a study of a live intranasal influenza vaccine in the immunization of children 3 to 15 years old].
    Rudenko LG; Grigor'eva EP; Drinevskiĭ VP; Koval' TA; Doroshenko EM
    Zh Mikrobiol Epidemiol Immunobiol; 1988 May; (5):41-6. PubMed ID: 2970743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.